Dataset Information

A dosing algorithm for individualized radioiodine treatment of cats with hyperthyroidism.

ABSTRACT:

Background

Radioiodine (¹³¹ I) is the treatment of choice for hyperthyroidism in cats, but current ¹³¹ I-dosing protocols can induce iatrogenic hypothyroidism and expose azotemia.

Objectives

To develop a cat-specific algorithm to calculate the lowest ¹³¹ I dose to resolve hyperthyroidism, while minimizing risk of iatrogenic hypothyroidism and subsequent azotemia.

Animals

One thousand and four hundred hyperthyroid cats treated with ¹³¹ I.

Methods

Prospective case series (before-and-after study). All cats had serum concentrations of thyroxine (T₄ ), triiodothyronine (T₃ ), and thyroid-stimulating hormone (TSH) measured (off methimazole ≥1 week). Using thyroid scintigraphy, each cat's thyroid volume and percent uptake of ^99m Tc-pertechnatate (TcTU) were determined. An initial ¹³¹ I dose was calculated by averaging dose scores for T₄ /T₃ concentrations, thyroid volume, and TcTU; 80% of that composite dose was administered. Twenty-four hours later, percent ¹³¹ I uptake was measured, and additional ¹³¹ I administered, as needed, to deliver an adequate radiation dose to the thyroid tumor(s). Serum concentrations of T₄ , TSH, and creatinine were determined 6 to 12 months later.

Results

The median calculated ¹³¹ I dose was 1.9 mCi (range, 1.0-10.6 mCi); 1380 cats required additional ¹³¹ I administration on day 2. Of the cats, 1047 (74.8%) became euthyroid, 57 (4.1%) became overtly hypothyroid, 240 (17.1%) became subclinically hypothyroid, and 56 (4%) remained hyperthyroid. More overtly (71.9%) and subclinically (39.6%) hypothyroid cats developed azotemia than euthyroid cats (14.2%; P < .0001).

Conclusions and clinical importance

Our algorithm for calculating individual ¹³¹ I doses resulted in cure rates similar to historical treatment rates, despite much lower ¹³¹ I doses. This algorithm appears to lower prevalence of both ¹³¹ I-induced overt hypothyroidism and azotemia.

SUBMITTER: Peterson ME

PROVIDER: S-EPMC8478068 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ObjectivesRadioiodine (131I) therapy is the most appropriate treatment option for many hyperthyroid cats, as it is minimally invasive and often curative. Nevertheless, 131I treatment is not always pursued by owners. Hence, it is important to obtain more insight into owner satisfaction during and after 131I treatment, and their decision-making process. In this study, we describe the characteristics of owners and their hyperthyroid cats referred for 131I therapy, and determine owners' motivation and how they experienced the 131I treatment of their cat.MethodsA survey was sent to owners whose cats underwent 131I therapy (n = 1071) between 2010 and 2017 at Ghent University. The survey contained 35 questions with tick-box or free-text answer options concerning family situation, pet insurance, previous therapy, comorbidities, motivation for 131I therapy and owner perception of this treatment.ResultsIn total, 438 owners completed 94% or more of the questionnaire. Over half of the cats (55%) had received previous medical, dietary or surgical treatment. Motivations for changing the initial therapy to 131I therapy included difficulties in administering medication (31%), insufficient improvement in clinical signs (23%), side effects (16%) and following the referring veterinarian's advice (16%). Almost a fifth of owners (18%) were not informed about the existence of 131I therapy by their veterinarian and found information on 131I treatment online or through friends. Hospitalising their cat was very distressing for 17% of owners. Most owners (92%) were satisfied with the treatment. Reasons for dissatisfaction were insufficient communication, iatrogenic hypothyroidism, persistent hyperthyroidism and comorbidities post-treatment.Conclusions and relevanceOur study stresses the importance of communication regarding the possible outcome of 131I treatment, the importance of managing underlying comorbidities before treatment and anticipating the stress of owners during their cat's hospitalisation period. The results of this study could help in improving client communication when advising on 131I treatment.